RICHMOND: Indivior PLC announced that effective today, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director.

Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.

Ryan Preblick, currently SVP Global Financial Planning and Analysis Commercial Operations, has been appointed interim Chief Financial Officer. Indivior will initiate a search for a permanent Chief Financial Officer and will assess whether to appoint a separate Operations Officer. As an interim appointee, Mr. Preblick will not be appointed as an Executive Director.

Ryan joined Indivior in 2012 as Regional Finance Controller (North America), later becoming VP U.S. Finance, responsible for Financial Planning & Analysis and Government Pricing. He was promoted to his current role in January 2020. Previously, he worked for fourteen years in various finance capacities at Altria Group and Honeywell International.

Comment by Daniel Tassé, Interim Chair of Indivior PLC: “Indivior’s vision is to ensure patients all around the world have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Mark is a proven leader with a broad strategic and financial skillset and a deep understanding of the Company’s guiding principles. The Board has full confidence in his ability to drive Indivior forwards and to pursue its vision for the benefit of all stakeholders. Shaun has played a key role since the formation of Indivior and on behalf of the Board we thank him for his significant contributions to Indivior and, in particular, his efforts to advance addiction treatment across our global communities.

“Indivior has a strong culture across all fronts of the business and I and the Board look forward to supporting Mark, the executive team and all of our colleagues in the months and years ahead.”

Comment by Mark Crossley, CEO of Indivior PLC: “I am honored to have been appointed as Chief Executive Officer of Indivior as we continue our work to change patients’ lives by developing medicines to treat addiction and serious mental health illnesses. In recent years, the Group has made excellent strategic progress on life-transforming treatments with the launch of SUBLOCADE and PERSERIS. There remains a very significant opportunity for Indivior in the years ahead, and I look forward to working with the Board to deliver the full potential of our key assets, to resolve outstanding investigations and litigations as expeditiously as possible, and to ensure that we continue to play a leading role in helping patients, doctors, and communities fight the human crisis of opioid addiction. Finally, I would like to take a moment to thank Shaun for his leadership at Indivior and significant contributions within the addiction treatment community.”

Comment by Shaun Thaxter: “It has been an honour and a privilege to lead the development of Indivior as it focused on empowering individuals to overcome their addiction. We have truly been pioneers in developing new treatments and helping to change patients’ lives. Indivior has a highly talented management and workforce. I am confident in their ability to deliver against its vision as I prepare for my next business challenge.”

Shaun Thaxter will be treated in accordance with Indivior’s approved remuneration policy and the terms of his service contract.  Full details of remuneration payable to Shaun Thaxter will be disclosed on the Indivior website in compliance with Section 430(2B) of the Companies Act 2006 and will be disclosed in the Company’s Annual Report and Accounts for the year ending December 31, 2020.